FUSION ANTIBODIES PLC (FAB) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the FUSION ANTIBODIES PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. Company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to CEO, Adrian Kincaid. Good morning. Thank you very much. Thank you everyone for joining us today. For those people who don't know me, my name is Adrian Kincaid. I am the CEO of FUSION ANTIBODIES. I'm joined today by Steven Smith, who is our interim CFO. You'll be hearing more from Steven in a short while. So let me let me kick off and tell you the latest about FUSION. We have, of course, the usual disclaimer, so I will assume that you've all speed read that. Thank you very much. So FUSION ANTIBODIES act as a contract research organization or CRO within the field of antibodies. Now the by far, the largest market for antibodies is therapeutics, but we mustn't forget there's also diagnostic applications and indeed research antibody markets as well. We focus on main market, antibody therapeutics, then you can see from these various market studies and highlights on on this slide that the market is absolutely vast. So it's been building from 253,000,000,000 in 2024 to projected value of very nearly 500,000,000,000 by 2029 if everything goes to plan, of course. Between 2020 and 2024, there've been 63 antibody therapeutics granted approv...